CapsoVision (CV) Common Equity (2024 - 2025)
CapsoVision (CV) reported Common Equity of $13.3 million for Q4 2025, up 110.24% on a YoY basis from $6.3 million in Q4 2024, and down 35.13% sequentially from $20.4 million in Q3 2025.
CapsoVision (CV) Common Equity (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of Common Equity data on file, last reported at $13.3 million in Q4 2025.
- For the quarter ending Q4 2025, Common Equity rose 110.24% year-over-year to $13.3 million; the trailing twelve-month figure through Dec 2025 stood at $13.3 million (up 110.24% YoY), and the FY2025 full-year result was $13.3 million, up 110.24% from the prior year.
- Common Equity slipped to $13.3 million in Q4 2025, from $20.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $20.4 million in Q3 2025 to a low of -$139.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 52.70 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 38.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 50.07 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.86 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 10.33 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 2.96 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 13.34 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.67 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 5.29 Bn |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn | 13.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.26 Mn |
| Sep 30, 2025 | 20.44 Mn |
| Jun 30, 2025 | -138.99 Mn |
| Dec 31, 2024 | -129.51 Mn |
| Sep 30, 2024 | -124.99 Mn |
| Jun 30, 2024 | -119.21 Mn |